The message was based in part on the results of four multicenter, open-label, two-period biological process studies screening that the 20-mg and 40-mg injections were similarly efficacious to the corresponding oral doses in suppressing acid after 10 days of use in patients with and without a continuum of erosive esophagitis.
Esomeprazole magnesium oral therapy (Nexium delayed-release capsules, made by AstraZeneca) is indicated for the aid of symptomatic GERD, the healing of erosive esophagitis, and to reduce the risk of nonsteroidal anti-inflammatory drug–associated gastric planetary house. It is also indicated for use in triplet therapy for Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence.
On Advance 25, the FDA approved an expanded indicant for ondansetron HCl insertion (Zofran, made by GlaxoSmithKline), allowing its use in infants aged one period and older for the prevention of postoperative sickness and vomiting (PONV), and in infants aged six months and older for the prevention of chemotherapy-induced sickness and vomiting (CINV).
Ondansetron was previously approved for prevention of PONV and CINV in patients aged two period of time and older.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment